No data to show
XNAS
BIAF
Market cap8mUSD
Jun 12, Last price
0.31USD
1D
3.64%
1Q
-16.89%
IPO
-96.33%
Name
bioAffinity Technologies Inc
Chart & Performance
P/E
—
P/S
0.93
EPS
—
Div Yield, %
—
Shrs. gr., 5y
10.93%
Rev. gr., 5y
%
Revenues
9m
+269.68%
Net income
-9m
L+13.89%
CFO
-7m
L+20.32%
Profile
bioAffinity Technologies, Inc., a biotechnology company, engages in developing non-invasive diagnostic tests and targeted cancer therapeutics. The company offers CyPath lung, a diagnostic test, for early detection of lung cancer. It also researches targeted therapies to treat cancer at the cellular level. The company was founded in 2014 and is based in San Antonio, Texas.
Valuation
Title USD in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|
| 2024‑12 | 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | |
| Income | ||||||
Revenues | 9,362 269.68% | 2,532 52,627.44% | 5 | |||
Cost of revenue | 7,766 | 3,465 | 4,016 | |||
Unusual Expense (Income) | ||||||
NOPBT | 1,596 | (933) | (4,011) | |||
NOPBT Margin | 17.04% | |||||
Operating Taxes | 12 | 21 | 2 | |||
Tax Rate | 0.73% | |||||
NOPAT | 1,584 | (954) | (4,014) | |||
Net income | (9,040) 13.89% | (7,937) -2.66% | (8,154) 28.89% | |||
Dividends | ||||||
Dividend yield | ||||||
Proceeds from repurchase of equity | 4,351 | 6,027 | ||||
BB yield | -38.58% | -83.73% | ||||
| Debt | ||||||
Debt current | 694 | 920 | 252 | |||
Long-term debt | 2,116 | 2,697 | ||||
Deferred revenue | ||||||
Other long-term liabilities | 597 | |||||
Net debt | 1,705 | 796 | (11,162) | |||
| Cash flow | ||||||
Cash from operating activities | (7,265) | (6,038) | (4,071) | |||
CAPEX | (23) | (220) | ||||
Cash from investing activities | (79) | (2,209) | (220) | |||
Cash from financing activities | 5,628 | (345) | 14,344 | |||
FCF | 1,960 | (2,734) | (4,620) | |||
| Balance | ||||||
Cash | 1,105 | 2,822 | 11,414 | |||
Long term investments | ||||||
Excess cash | 637 | 2,695 | 11,414 | |||
Stockholders' equity | (53,538) | (44,539) | 12,145,516 | |||
Invested Capital | 57,641 | 51,433 | (118) | |||
ROIC | 2.90% | |||||
ROCE | 38.89% | |||||
| EV | ||||||
Common stock shares outstanding | 12,392 | 8,748 | 4,499 | |||
Price | 0.91 -38.12% | 1.47 -8.09% | 1.60 | |||
Market cap | 11,277 -12.33% | 12,863 78.70% | 7,198 | |||
EV | 12,982 | 13,659 | 12,178,161 | |||
EBITDA | 1,596 | (683) | (4,001) | |||
EV/EBITDA | 8.14 | |||||
Interest | 92 | 37 | 2,533 | |||
Interest/NOPBT | 5.80% | |||||